The effect of peroral calcitriol in small doses on mild secondary hyperparathyroidism in patients on hemodialysis.
Our prospective 1-year study comprises 93 patients of both sexes, various ages and various dialysis duration. Among them, 31 patients with a concentration of Ca in blood under 2.7 mmol/l, a concentration of P under 1.8 mmol/l and a concentration of PTHi over 65 pg/ml (group 0) received calcitriol 0.25 microgramx418p4The control group consisted of patients not receiving calcitriol and having normal Ca and P metabolism (group 1). The rest of the patients had a concentration of P over 1.8 mmol/l and could not be given calcitriol. A comparison of the dynamics of average plasmic concentrations of Ca, P, AP, PTHi and X-ray changes in group 0 and 1 at the beginning of the investigation and 1 year later was carried out. At the termination of the 1-year treatment, when compared to the initial state, a statistically significant increase in the concentration of Ca (p < 0.005) and in the concentration of P (p < 0.005) was noted in group 0. The average concentration of PTHi decreased to the desired level, the X-ray changes characteristic of secondary hyperparathyroidism progressed more slowly in group 0.
Pecovnik-Balon
B
B
Department of Nephrology, Maribor Teaching Hospital, Slovenia.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D002117:Calcitriol / Q000008:administration & dosage / Q000627:therapeutic use*; D002118:Calcium / Q000097:blood; D005260:Female; D006801:Humans; D006961:Hyperparathyroidism / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood; D010710:Phosphates / Q000097:blood; D011446:Prospective Studies; D006435:Renal Dialysis / Q000009:adverse effects*
D010281:Parathyroid Hormone; D010710:Phosphates; D000469:Alkaline Phosphatase; D002117:Calcitriol; D002118:Calcium